CYP4F59P: A Drug Target / Disease Biomarker (G100132340)

Target Name: CYP4F59P

NCBI ID: G100132340

CYP4F59P

Other Name(s): Cytochrome P450, family 4, subfamily F, polypeptide 59, pseudogene | cytochrome P450 family 4 subfamily F member 59, pseudogene

CYP4F59P: A Drug Target / Disease Biomarker

CYP4F59P is a protein that is expressed in many tissues throughout the body, including the brain, heart, and kidneys. It is a member of the C-type cytoskeleton protein family and is involved in the regulation of cell shape and movement.

One of the unique features of CYP4F59P is its ability to interact with various drug molecules, making it a promising drug target. The protein is known to interact with a wide range of drugs, including many anti-cancer drugs, and is also a known carrier protein for many drugs, including paclitaxel and the anti-inflammatory drug celecoxib.

This interactivity between CYP4F59P and drugs has led to the development of new drug treatments for a range of diseases. For example, studies have shown that inhibiting CYP4F59P can lead to increased drug levels and reduced efficacy of certain anti-cancer drugs. Additionally, drugs that interact with CYP4F59P have been shown to be more effective in treating certain diseases, such as heart failure and certain types of cancer.

CYP4F59P is also of interest as a potential biomarker for disease. The protein is often expressed at higher levels in tissues that are affected by a given disease, and can be used as a diagnostic marker for a range of conditions, including cancer, neurodegenerative diseases, and cardiovascular diseases.

One of the challenges in studying CYP4F59P as a drug target is its complex structure. The protein is composed of multiple domains, including an N-terminus that is involved in protein-protein interactions and a C-terminus that is involved in cell surface interactions. The structure of CYP4F59P is also highly conserved, which can make it difficult to study.

Despite these challenges, researchers are making significant progress in the study of CYP4F59P and its potential as a drug target. Many studies have shown that inhibiting CYP4F59P can lead to the inhibition of various cellular processes that are involved in disease, such as cell growth, angiogenesis, and inflammation. Additionally, several compounds have been shown to be CYP4F59P inhibitors and have been tested as potential drugs for a range of diseases.

In conclusion, CYP4F59P is a protein that is involved in the regulation of cell shape and movement and has been shown to interact with a wide range of drugs, including many anti-cancer drugs. Its complex structure and high conservation have made it difficult to study, but researchers are making significant progress in the study of its potential as a drug target. Further studies are needed to fully understand the role of CYP4F59P in disease and to develop new treatments for a range of conditions.

Protein Name: Cytochrome P450 Family 4 Subfamily F Member 59, Pseudogene

The "CYP4F59P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP4F59P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets